Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.

Brain pathology (Zurich, Switzerland) - 1 Jan 2011

von Deimling Andreas, Korshunov Andrey, Hartmann Christian

Abstract excerpt

For some, glioma biomarkers have been expected to solve common diagnostic problems in routine neuropathology service caused by insufficient material, technical shortcomings or lack of experience. Further, biomarkers should predict patient outcome and direct optimal therapy for the individual patient. Unfortunately, current biomarkers still fall somewhat short of these grand expectations. While there has been some...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to DNA Modification Methylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair Enzymes

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Methylation

Share to Proto-Oncogene Proteins B-raf

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21129061
DOI: 10.1111/j.1750-3639.2010.00454.x
PMCID: PMC8094257

Genes

BRAF
IDH1
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.PMID 21129061Read ↗

Predictive and Prognostic Significance of Molecular Biomarkers in GlioblastomaSemantic proximity Read ↗

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme.Semantic proximity Read ↗

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesSemantic proximity Read ↗

Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.Semantic proximity Read ↗

Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance.Semantic proximity Read ↗

Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapiesSemantic proximity Read ↗

Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.Semantic proximity Read ↗

Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusSemantic proximity Read ↗

O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.Semantic proximity Read ↗

Diagnostic and prognostic markers in gliomas - an update.Semantic proximity Read ↗

Molecular biology of high-grade gliomas: what should the clinician know?Semantic proximity Read ↗

IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.